Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C DallosAleksandar Z ObradovicPatrick McCannNivedita ChowdhuryAditya PratapaDavid Henry AggenChristopher D GaffneyKaren A AutioRenu K VirkAngelo M DeMarzoEmmanuel S AntonarakisHoward I ScherCharles G DrakeDana E RathkopfPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
These observations underscore the critical role of timing and disease context in order to optimize the therapeutic efficacy of immune modulators combined with androgen ablation, for which the presurgical neoadjuvant setting may be ideal. Our findings warrant future prospective validation, which is currently underway.